Allarity Therapeutics (ALLR) Share-based Compensation (2020 - 2026)
Allarity Therapeutics' (ALLR) quarterly Share-based Compensation came in at $1.5 million in Q1 2026, up 979.14% YoY from $139000.0 in Q1 2025, and up 650.0% on a QoQ basis from $200000.0 in Q4 2025.
Allarity Therapeutics (ALLR) Share-based Compensation (2020 - 2026) Analysis & Trends
Allarity Therapeutics (ALLR) has 7 years of Share-based Compensation data on file, last reported at $1.5 million in Q1 2026.
- Quarterly Share-based Compensation rose 979.14% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (up 519.83% YoY) and the FY2025 annual result came in at $200000.0, down 33.33% from the prior year.
- Share-based Compensation rose to $1.5 million in Q1 2026, from $200000.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $1.5 million in Q1 2026 to a low of -$254000.0 in Q4 2023.
- A 5-year average of $239117.6 and a median of $139000.0 in 2025 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2023 — Share-based Compensation plunged 174.71% — and 2026, when it jumped 979.14%.
- Tracing ALLR's Share-based Compensation over 5 years: stood at $340000.0 in 2022, then sank by 174.71% to -$254000.0 in 2023, then soared by 125.2% to $64000.0 in 2024, then soared by 212.5% to $200000.0 in 2025, then jumped by 650.0% to $1.5 million in 2026.
- The last three Share-based Compensation figures came in at $1.5 million (Q1 2026), $200000.0 (Q4 2025), and $132000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.01 Bn | 132.16 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.79 Bn | 78.79 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.18 Bn | 55.04 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.55 Bn | 28.24 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.45 Bn | 10.06 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.19 Bn | 26.36 Bn | - | - |
| 10 | Allarity Therapeutics | 23.07 Mn | 23.07 Mn | - | 188,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.50 Mn |
| Mar 31, 2026 | 1.50 Mn |
| Dec 31, 2025 | 200,000.00 |
| Dec 31, 2025 | 200,000.00 |
| Sep 30, 2025 | 132,000.00 |
| Sep 30, 2025 | 132,000.00 |
| Jun 30, 2025 | 164,000.00 |
| Jun 30, 2025 | 164,000.00 |
| Mar 31, 2025 | 139,000.00 |
| Mar 31, 2025 | 139,000.00 |
| Dec 31, 2024 | 64,000.00 |
| Dec 31, 2024 | 64,000.00 |
| Sep 30, 2024 | 17,000.00 |
| Sep 30, 2024 | 17,000.00 |
| Jun 30, 2024 | 22,000.00 |
| Jun 30, 2024 | 22,000.00 |
| Mar 31, 2024 | 90,000.00 |
| Mar 31, 2024 | 90,000.00 |
| Dec 31, 2023 | -254,000.00 |
| Dec 31, 2023 | -254,000.00 |